Top

Published in:

01-08-2017 | Review

Nrf2: a potential therapeutic target for diabetic neuropathy

Authors: Anil Kumar, Ruchika Mittal

Published in: Inflammopharmacology | Issue 4/2017

Abstract

Different aspects involved in pathophysiology of diabetic neuropathy are related to inflammatory and apoptotic pathways. This article summarizes evidence that Nrf2 acts as a bridging link in various inflammatory and apoptotic pathways impacting progression of diabetic neuropathy. Nrf2 is involved in expression of various antioxidant proteins (such as detoxifying enzymes) via antioxidant response element (ARE) binding site. Under normal conditions, Nrf2 is inactive and remains in the cytosol. Hyperglycemia is a strong stimulus for oxidative stress and inflammation that downregulates the activity of Nrf2 through various neuroinflammatory pathways. Acute hyperglycemia increases the expression of Nrf2, but persistent hyperglycemia decreases its expression. This downregulation of Nrf2 causes various microvascular changes, which result in diabetic neuropathy. The key contribution of Nrf2 in progression of diabetic neuropathy has been summarized in the article. Despite involvement of Nrf2 in progression of diabetic neuropathy, targeting Nrf2 activators as a therapeutic potential will provide important new insights into the ways that influence treatment of diabetic neuropathy.

Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D (2006) Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 281:35764–35769CrossRefPubMed

Atia A, Abdullah A (2014) The Nrf2-Keap1 signalling pathway: Mechanisms of ARE transcription regulation in antioxidant cellular defence. Int J Pharm Tech Res 6:154–167

Babu PS, Prabuseenivasan S, Ignacimuthu S (2007) Cinnamaldehyde—a potential antidiabetic agent. Phytomedicine 14:15–22CrossRef

Bertelli AA, Das DK (2009) Grapes, wines, resveratrol, and heart health. J Cardiovasc Pharmacol 54:468–476CrossRefPubMed

Bhakkiyalakshmi E, Sireesh D, Rajaguru P, Paulmurugan R, Ramkumar KM (2015) The emerging role of redox-sensitive Nrf2–Keap1 pathway in diabetes. Pharmacol Res 91:104–114CrossRefPubMed

Bloom DA, Jaiswal AK (2003) Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem 278:44675–44682CrossRefPubMed

Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefPubMed

Bryan HK, Olayanju A, Goldring CE, Park BK (2013) The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 85:705–717CrossRefPubMed

Cameron NE, Cotter MA (2008) Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets 9:60–67CrossRefPubMed

Choi BH, Kang KS, Kwak MK (2014) Effect of redox modulating NRF2 activators on chronic kidney disease. Molecules 19:12727–12759CrossRefPubMed

Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA (2003) Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23:7198–7209CrossRefPubMedPubMedCentral

de Haan JB (2011) Nrf2 activators as attractive therapeutics for diabetic nephropathy. Diabetes 60:2683–2684CrossRefPubMedPubMedCentral

Ding M, Zhao J, Bowman L, Lu Y, Shi X (2010) Inhibition of AP-1 and MAPK signaling and activation of Nrf2/ARE pathway by quercitrin. Int J Oncol 36:59–67PubMed

Dinkova-Kostova AT et al (2005) Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 102:4584–4589CrossRefPubMedPubMedCentral

El-Bassossy HM, Fahmy A, Badawy D (2011) Cinnamaldehyde protects from the hypertension associated with diabetes. Food Chem Toxicol 49:3007–3012CrossRefPubMed

Evcimen ND, King GL (2007) The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 55:498–510CrossRefPubMed

Fahey JW, Talalay P (1999) Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 37:973–979CrossRefPubMed

Gonzalez-Reyes S, Guzman-Beltran S, Medina-Campos ON, Pedraza-Chaverri J (2013) Curcumin pretreatment induces Nrf2 and an antioxidant response and prevents hemin-induced toxicity in primary cultures of cerebellar granule neurons of rats. Oxid Med Cell Longev 2013:801418CrossRefPubMedPubMedCentral

Guo Y, Yu S, Zhang C, Kong AN (2015) Epigenetic regulation of Keap1-Nrf2 signaling. Free Radic Biol Med 88:337–349CrossRefPubMedPubMedCentral

Gupta SC, Patchva S, Koh W, Aggarwal BB (2012) Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 39:283–299CrossRefPubMedPubMedCentral

He HJ, Wang GY, Gao Y, Ling WH, Yu ZW, Jin TR (2012) Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice. World J Diabetes 3:94–104CrossRefPubMedPubMedCentral

Holland R, Fishbein JC (2010) Chemistry of the cysteine sensors in Kelch-like ECH-associated protein 1. Antioxid Redox Signal 13:1749–1761CrossRefPubMedPubMedCentral

Hong F, Freeman ML, Liebler DC (2005) Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol 18:1917–1926CrossRefPubMed

Huang HC, Nguyen T, Pickett CB (2002) Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 277:42769–42774CrossRefPubMed

Huang TC, Chung YL, Wu ML, Chuang SM (2011) Cinnamaldehyde enhances Nrf2 nuclear translocation to upregulate phase II detoxifying enzyme expression in HepG2 cells. J Agric Food Chem 59:5164–5171CrossRefPubMed

Li W et al (2008) Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol 76:1485–1489CrossRefPubMedPubMedCentral

Liao JC et al (2012) Anti-inflammatory activities of Cinnamomum cassia constituents in vitro and in vivo. Evid Based Complement Alternat Med 2012:429320PubMedPubMedCentral

Miseta A, Csutora P (2000) Relationship between the occurrence of cysteine in proteins and the complexity of organisms. Mol Biol Evol 17:1232–1239CrossRefPubMed

Moi P, Chan K, Asunis I, Cao A, Kan YW (1994) Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 91:9926–9930CrossRefPubMedPubMedCentral

Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M et al (2013) Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Altern Med 2013:851267CrossRef

Negi G, Kumar A, Sharma SS (2011) Nrf2 and NF-kappaB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes. Curr Neurovasc Res 8:294–304CrossRefPubMed

Negi G, Nakkina V, Kamble P, Sharma SS (2015) Heme oxygenase-1, a novel target for the treatment of diabetic complications: focus on diabetic peripheral neuropathy. Pharmacol Res 102:158–167CrossRefPubMed

Nioi P, Nguyen T, Sherrattm PJ, Pickett CB (2005) The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol Cell Biol 25:10895–10906CrossRefPubMedPubMedCentral

Oates PJ (2008) Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 9:14–36CrossRefPubMed

Palsamy P, Subramanian S (2011) Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2–Keap1 signaling. Biochim Biophys Acta 1812:719–731CrossRefPubMed

Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, Cuadrado A (2011) SCF/β-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 31:1121–1133CrossRefPubMedPubMedCentral

Rada P et al (2012) Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis. Mol Cell Biol 32:3486–3499CrossRefPubMedPubMedCentral

Reisman SA et al (2015) Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers. BMC Dermatol 15:10CrossRefPubMedPubMedCentral

Rojo AI, Sagarra MR, Cuadrado A (2008) GSK-3β down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 105:192–202CrossRefPubMed

Schmidt EE (2015) Interplay between cytosolic disulfide reductase systems and the Nrf2/Keap1 pathway. Biochem Soc Trans 43:632–638CrossRefPubMedPubMedCentral

Shakeel M (2015) Recent advances in understanding the role of oxidative stress in diabetic neuropathy. Diabetes Metab Syndr Clin Res Rev 9:373–378CrossRef

Sharma SS, Kumar A, Kaundal RK (2008) Protective effects of 4-amino 1,8-naphthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy. Life Sci 82:570–576CrossRefPubMed

Song MY, Kim EK, Moon WS, Park JW, Kim HJ, So HS et al (2009) Sulforaphane protects against cytokine- and streptozotocin-induced beta-cell damage by suppressing the NF-kappaB pathway. Toxicol Appl Pharmacol 235:57–67CrossRefPubMed

Stefanson AL, Bakovic M (2014) Dietary regulation of Keap1/Nrf2/ARE pathway: focus on plant-derived compounds and trace minerals. Nutrients 6:3777–3801CrossRefPubMedPubMedCentral

Sun Z, Chin YE, Zhang DD (2009a) Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response. Mol Cell Biol 29:2658–2672CrossRefPubMedPubMedCentral

Sun Z, Huang Z, Zhang DD (2009b) Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PLoS One 4:e6588CrossRefPubMedPubMedCentral

Tian R et al (2016) Rutin ameliorates diabetic neuropathy by lowering plasma glucose and decreasing oxidative stress via Nrf2 signaling pathway in rats. Eur J Pharmacol 771:84–92CrossRefPubMed

Tong KI, Kobayashi A, Katsuoka F, Yamamoto M (2006) Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol Chem 387:1311–1320CrossRefPubMed

Trujillo J, Chirino YI, Molina-Jijon E et al (2013) Renoprotective effect of the antioxidant curcumin: recent findings. Redox Biol 1:1–9CrossRef

Vincent AM, Edwards JL, Sadidi M, Feldman EL (2008) The antioxidant response as a drug target in diabetic neuropathy. Curr Drug Targets 9:94–100CrossRefPubMed

Wada R, Yagihashi S (2005) Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 1043:598–604CrossRefPubMed

Wang Y, Sun W, Du B, Miao X, Bai Y, Xin Y et al (2013) Therapeutic effect of MG-132on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-kappaB. Am J Physiol Heart Circ Physiol 304:H567–H578CrossRefPubMed

Wardyn JD, Ponsford AH, Sanderson CM (2015) Dissecting molecular cross-talk between Nrf2 and NF-kappaB response pathways. Biochem Soc Trans 43:621–626CrossRefPubMedPubMedCentral

Wondrak GT, Cabello CM, Villeneuve NF, Zhang S, Ley S, Li Y et al (2008) Cinnamoyl-based Nrf2-activators targeting human skin cell photo-oxidative stress. Free Radic Biol Med 45:385–395CrossRefPubMedPubMedCentral

Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D et al (2011) Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60:3055–3066CrossRefPubMedPubMedCentral

Zipper LM, Mulcahy RT (2000) Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes. Biochem Biophys Res Commun 278:484–492CrossRefPubMed

Title: Nrf2: a potential therapeutic target for diabetic neuropathy
Authors: Anil Kumar
Ruchika Mittal
Publication date: 01-08-2017
Publisher: Springer International Publishing
Published in: Inflammopharmacology / Issue 4/2017
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-017-0339-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Nrf2: a potential therapeutic target for diabetic neuropathy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Effects of antirheumatic drug underutilization on rheumatoid arthritis disease activity

Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)

Erratum to: Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy

Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson’s disease dementia in rats

Role of LPS-elicited signaling in triggering gastric mucosal inflammatory responses to H. pylori: modulatory effect of ghrelin

Melatonin as an anti-inflammatory agent in radiotherapy